PL3632904T3 - Inhibitory urat1 do pobudzania wydalania kwasu moczowego - Google Patents
Inhibitory urat1 do pobudzania wydalania kwasu moczowegoInfo
- Publication number
- PL3632904T3 PL3632904T3 PL18806684.9T PL18806684T PL3632904T3 PL 3632904 T3 PL3632904 T3 PL 3632904T3 PL 18806684 T PL18806684 T PL 18806684T PL 3632904 T3 PL3632904 T3 PL 3632904T3
- Authority
- PL
- Poland
- Prior art keywords
- uric acid
- acid excretion
- promoting uric
- urat1 inhibitors
- urat1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710386922 | 2017-05-26 | ||
PCT/CN2018/088400 WO2018214961A1 (zh) | 2017-05-26 | 2018-05-25 | 促尿酸排泄的urat1抑制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3632904T3 true PL3632904T3 (pl) | 2022-08-22 |
Family
ID=63352281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL18806684.9T PL3632904T3 (pl) | 2017-05-26 | 2018-05-25 | Inhibitory urat1 do pobudzania wydalania kwasu moczowego |
Country Status (11)
Country | Link |
---|---|
US (1) | US11597725B2 (pl) |
EP (1) | EP3632904B1 (pl) |
JP (1) | JP6915907B2 (pl) |
KR (1) | KR102420892B1 (pl) |
CN (1) | CN108484600B (pl) |
CA (1) | CA3066680C (pl) |
DK (1) | DK3632904T3 (pl) |
ES (1) | ES2912941T3 (pl) |
MX (1) | MX2019014078A (pl) |
PL (1) | PL3632904T3 (pl) |
WO (1) | WO2018214961A1 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111410654B (zh) * | 2019-01-19 | 2022-05-17 | 江苏新元素医药科技有限公司 | 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成 |
CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
CN114127078B (zh) * | 2019-06-17 | 2024-03-01 | 重庆复创医药研究有限公司 | 杂化合物及其使用方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1565734A (en) * | 1977-05-03 | 1980-04-23 | Laroche Navarron Sa | Fused triazoles |
NZ193926A (en) * | 1979-07-06 | 1984-05-31 | Labaz Sanofi Nv | 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines |
AR042067A1 (es) * | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
BRPI0619252A2 (pt) * | 2005-11-30 | 2011-09-20 | Vertex Pharma | inibidores de c-met e seus usos |
US8735386B2 (en) * | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
WO2012048058A2 (en) * | 2010-10-06 | 2012-04-12 | J-Pharma Co., Ltd. | Developing potent urate transporter inhibitors: compounds designed for their uricosuric action |
GB201321743D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CN106065010B (zh) * | 2015-04-23 | 2019-01-01 | 镇江新元素医药科技有限公司 | 用于治疗或预防高尿酸血症或痛风的化合物 |
EA037280B1 (ru) * | 2015-09-10 | 2021-03-03 | Цзянсу Атом Байосайенс Энд Фармасьютикал Ко., Лтд. | Группа соединений, применяющихся для лечения или предупреждения гиперурикемии или подагры |
CN106433229A (zh) * | 2016-08-29 | 2017-02-22 | 无锡双诚炭黑有限公司 | 油炉法炭黑反应装置及其反应方法 |
CN108084186B (zh) * | 2016-11-16 | 2021-06-25 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
WO2018090921A1 (zh) * | 2016-11-16 | 2018-05-24 | 江苏新元素医药科技有限公司 | Urat1抑制剂及其应用 |
-
2018
- 2018-05-25 CN CN201810517139.1A patent/CN108484600B/zh active Active
- 2018-05-25 MX MX2019014078A patent/MX2019014078A/es unknown
- 2018-05-25 PL PL18806684.9T patent/PL3632904T3/pl unknown
- 2018-05-25 EP EP18806684.9A patent/EP3632904B1/en active Active
- 2018-05-25 US US16/617,426 patent/US11597725B2/en active Active
- 2018-05-25 KR KR1020197038336A patent/KR102420892B1/ko active IP Right Grant
- 2018-05-25 DK DK18806684.9T patent/DK3632904T3/da active
- 2018-05-25 CA CA3066680A patent/CA3066680C/en active Active
- 2018-05-25 JP JP2019565209A patent/JP6915907B2/ja active Active
- 2018-05-25 ES ES18806684T patent/ES2912941T3/es active Active
- 2018-05-25 WO PCT/CN2018/088400 patent/WO2018214961A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200011974A (ko) | 2020-02-04 |
CA3066680C (en) | 2022-04-12 |
MX2019014078A (es) | 2020-08-03 |
US20200262832A1 (en) | 2020-08-20 |
EP3632904A4 (en) | 2021-03-03 |
ES2912941T3 (es) | 2022-05-30 |
WO2018214961A1 (zh) | 2018-11-29 |
US11597725B2 (en) | 2023-03-07 |
KR102420892B1 (ko) | 2022-07-14 |
JP6915907B2 (ja) | 2021-08-04 |
JP2020521757A (ja) | 2020-07-27 |
CN108484600A (zh) | 2018-09-04 |
CA3066680A1 (en) | 2018-11-29 |
CN108484600B (zh) | 2022-12-13 |
EP3632904A1 (en) | 2020-04-08 |
DK3632904T3 (da) | 2022-07-25 |
EP3632904B1 (en) | 2022-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291099A (en) | Aminothiazole compounds as c–kit inhibitors | |
HK1249905A1 (zh) | 作為lsd1抑制劑的雜環化合物 | |
LT3371190T (lt) | Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai | |
HRP20190514T1 (hr) | Derivati 5-[(piperazin-1-il)-3-okso-propil]-imidazolidin-2,4-diona kao adamts inhibitori za liječenje osteoartritisa | |
EP3156397A4 (en) | Nitrogen-containing heterocyclic compound | |
EP3144308A4 (en) | Nitrogen-containing heterocyclic compound | |
IL279949A (en) | Heterocyclic MCT4 inhibitors | |
GB2540917B (en) | Solid acid scale inhibitors | |
EP3303324A4 (en) | Novel corrosion inhibitors | |
IL246345A0 (en) | History of 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid as neprilysin inhibitors | |
PT3481819T (pt) | Compostos e a sua utilização para reduzir os níveis de ácido úrico | |
IL281740A (en) | Compounds for reducing serum uric acid | |
PL3632904T3 (pl) | Inhibitory urat1 do pobudzania wydalania kwasu moczowego | |
IL248567A0 (en) | Using compounds known as d-amino acid oxidase inhibitors | |
EP3357907A4 (en) | Maleic acid salt of a silodosin intermediate | |
IL269073A (en) | Crystalline forms of obeticholic acid | |
SG11202001327RA (en) | Composition for reducing serum uric acid level |